{'fraction_non_alphanumeric': 0.02034428794992175, 'fraction_numerical': 0.00782472613458529, 'mean_word_length': 5.530612244897959, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
TMEM97 is a potential amyloid beta receptor in human Alzheimer’s disease synapses

Synapse loss correlates strongly with cognitive decline in Alzheimer’s disease (AD), and abundant evidence from animal and cell models implicates soluble amyloid beta in synaptic dysfunction and loss. While many candidate synaptic receptors for amyloid beta have been observed in model systems, the physiologically relevant amyloid beta receptor(s) involved in synapse degeneration in human AD brain remain unknown. Here we tested the hypothesis that TMEM97, recently discovered to be the sigma 2 receptor, binds amyloid beta in synapses in human AD brain.